Compare Oklo Inc (OKLO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Zimmer Biomet Holdings Inc — how do they compare? Oklo Inc trades at $34.32 (market cap $6.43B), while Zimmer Biomet Holdings Inc trades at $89.07 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.6× Oklo Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 31 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| OKLO | ZBH | |
|---|---|---|
Market Cap | $6.43B | $16.95B |
Volume | 16,238,368 | 2,505,240 |
Sector | Utilities | Health |
52-Week High | $174.14 | $103.98 |
52-Week Low | $34.57 | $79.58 |
Typical Hold Time | 31 Days | 89 Days |
Enterprise Value | $3.97B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $34.29, down 6.88% on the day, with bearish technical signals and negative earnings momentum. The company shows no revenue in 2025 and substantial losses, though it maintains strong analyst support with a $78.63 consensus price target. Recent news highlights nuclear energy sector volatility and OKLO's $1 billion stock sale activity.
OKLO represents a high-risk, high-reward opportunity in the emerging nuclear sector. While analyst consensus remains strongly bullish, the company faces significant execution risks, negative profitability, and dilution concerns from recent financing activities. The stock's potential hinges on successful project commercialization in the growing nuclear energy market.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
